Page 783 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 33 Hematopoietic Tumors 761

370. Williams LE, Rassnick KM, Power HT, et al.: CCNU in the 388. Kiupel M, Bostock D, Bergmann V: The prognostic significance of
treatment of canine epitheliotropic lymphoma, J Vet Intern Med AgNOR counts and PCNA-positive cell counts in canine malig-
20:136–143, 2006. nant lymphomas, J Comp Pathol 119:407–418, 1998.
VetBooks.ir 371. White SD, Rosychuk RA, Scott KV, et al.: Use of isotretinoin and 389. Larue SM, Fox MH, Ogilvie GK, et al.: Tumour cell kinetics as
predictors of response in canine lymphoma treated with chemo-
etretinate for the treatment of benign cutaneous neoplasia and
cutaneous lymphoma in dogs, J Am Vet Med Assoc 202:387–391,
1993. therapy alone or combined with whole body hyperthermia, Int J
Hyperthermia 15:475–486, 1999.
372. Moriello KAME, Schultz KT: PEG-asparaginase in the treatment 390. Miller AG, Morley PS, Rao S, et al.: Anemia is associated with
of canine epitheliotrophic lymphoma and histiocytic proleferative decreased survival time in dogs with lymphoma, J Vet Intern Med
dermatitis. In Ihrke PJMI, White SD, editors: Advances in Veteri- 23:116–122, 2009.
nary Dermatology, New York, 1993, Perggamon Press. 391. Rao S, Lana S, Eickhoff J, et al.: Class II major histocompatibility
373. Tzannes S, Ibarrola P, Batchelor DJ, et al.: Use of recombinant complex expression and cell size independently predict survival in
human interferon alpha-2a in the management of a dog with epith- canine B-cell lymphoma, J Vet Intern Med 25:1097–1105, 2011.
eliotropic lymphoma, J Am Anim Hosp Assoc 44:276–282, 2008. 392. Vaughan A, Johnson JL, Williams LE: Impact of chemotherapeutic
374. Rechner KN, Weeks KJ, Pruitt AF: Total skin electron therapy dose intensity and hematologic toxicity on first remission duration
technique for the canine patient, Vet Radiol Ultrasound 52:345– in dogs with lymphoma treated with a chemoradiotherapy proto-
352, 2011. col, J Vet Intern Med 21:1332–1339, 2007.
375. Childress MO, Ramos-Vara JA, Ruple A: Retrospective analysis of 393. Yamazaki J, Takahashi M, Setoguchi A, et al.: Monitoring of mini-
factors affecting clinical outcome following CHOP-based chemo- mal residual disease (MRD) after multidrug chemotherapy and its
therapy in dogs with primary nodal diffuse large B-cell lymphoma, correlation to outcome in dogs with lymphoma: a proof-of-concept
Vet Comp Oncol 16:E159–E168, 2018. pilot study, J Vet Intern Med 24:897–903, 2010.
376. Davies O, Szladovits B, Polton G, et al.: Prognostic significance of 394. Williams MJ, Avery AC, Lana SE, et al.: Canine lymphoprolifera-
clinical presentation, induction and rescue treatment in 42 cases of tive disease characterized by lymphocytosis: immunophenotypic
canine centroblastic diffuse large B-cell multicentric lymphoma in markers of prognosis, J Vet Intern Med 22:596–601, 2008.
the United Kingdom, Vet Comp Oncol 16:276–287, 2018. 395. Cook AK, Wright ZM, Suchodolski JS, et al.: Prevalence and prog-
377. Fontaine SJ, McCulloch E, Eckersall PD, et al.: Evaluation of the nostic impact of hypocobalaminemia in dogs with lymphoma,
modified Glasgow Prognostic Score to predict outcome in dogs J Am Vet Med Assoc 235:1437–1441, 2009.
with newly diagnosed lymphoma, Vet Comp Oncol 15:1513–1526, 396. von Euler H, Einarsson R, Olsson U, et al.: Serum thymidine
2017. kinase activity in dogs with malignant lymphoma: a potent marker
378. Koshino A, Goto-Koshino Y, Setoguchi A, et al.: Mutation of p53 for prognosis and monitoring the disease, J Vet Intern Med 18:696–
gene and its correlation with the clinical outcome in dogs with lym- 702, 2004.
phoma, J Vet Intern Med 30:223–229, 2016. 397. Von Euler HP, Rivera P, Aronsson AC, et al.: Monitoring therapy in
379. Romano FR, Heinze CR, Barber LG, et al.: Association between canine malignant lymphoma and leukemia with serum thymidine
body condition score and cancer prognosis in dogs with lymphoma kinase 1 activity—evaluation of a new, fully automated non-radio-
and osteosarcoma, J Vet Intern Med 30:1179–1186, 2016. metric assay, Int J Oncol 34:505–510, 2009.
380. Sierra Matiz OR, Santilli J, Anai LA, et al.: Prognostic significance 398. Baskin CR, Couto CG, Wittum TE: Factors influencing first
of Ki67 and its correlation with mitotic index in dogs with diffuse remission and survival in 145 dogs with lymphoma: a retrospective
large B-cell lymphoma treated with 19-week CHOP-based proto- study, J Am Anim Hosp Assoc 36:404–409, 2000.
col, J Vet Diagn Invest 1040638717743280, 2017. 399. Adam F, Villiers E, Watson S, et al.: Clinical pathological and epi-
381. Wang SL, Lee JJ, Liao AT: Chemotherapy-induced neutropenia is demiological assessment of morphologically and immunologically
associated with prolonged remission duration and survival time in confirmed canine leukaemia, Vet Comp Oncol 7:181–195, 2009.
canine lymphoma, Vet J 205:69–73, 2015. 400. Comazzi S, Gelain ME, Martini V, et al.: Immunophenotype pre-
382. Marconato L, Martini V, Stefanello D, et al.: Peripheral blood lym- dicts survival time in dogs with chronic lymphocytic leukemia, J Vet
phocyte/monocyte ratio as a useful prognostic factor in dogs with Intern Med 25:100–106, 2011.
diffuse large B-cell lymphoma receiving chemoimmunotherapy, Vet 401. Roode SC, Rotroff D, Avery AC, et al.: Genome-wide assessment
J 206:226–230, 2015. of recurrent genomic imbalances in canine leukemia identifies evo-
383. Wilson-Robles H, Budke CM, Miller T, et al.: Geographical dif- lutionarily conserved regions for subtype differentiation, Chromo-
ferences in survival of dogs with non-Hodgkin lymphoma treated some Res 23:681–708, 2015.
with a CHOP based chemotherapy protocol, Vet Comp Oncol 402. Gioia G, Mortarino M, Gelain ME, et al.: Immunophenotype-
15:1564–1571, 2017. related microRNA expression in canine chronic lymphocytic leu-
384. Zamani-Ahmadmahmudi M, Aghasharif S, Ilbeigi K: Prognostic kemia, Vet Immunol Immunopathol 142:228–235, 2011.
efficacy of the human B-cell lymphoma prognostic genes in pre- 403. Stokol T, Schaefer DM, Shuman M, et al.: Alkaline phosphatase
dicting disease-free survival (DFS) in the canine counterpart, BMC is a useful cytochemical marker for the diagnosis of acute myelo-
Vet Res 13:17, 2017. monocytic and monocytic leukemia in the dog, Vet Clin Pathol
385. Zamani-Ahmadmahmudi M, Najafi A, Nassiri SM: Detection of 44:79–93, 2015.
critical genes associated with overall survival (OS) and progression- 404. Bennett AL, Williams LE, Ferguson MW, et al.: Canine acute leu-
free survival (PFS) in reconstructed canine B-cell lymphoma gene kaemia: 50 cases (1989-2014), Vet Comp Oncol 15:1101–1114,
regulatory network (GRN), Cancer Invest 34:70–79, 2016. 2017.
386. Abbo AH, Lucroy MD: Assessment of anemia as an independent 405. Leifer CE, Matus RE: Chronic lymphocytic leukemia in the dog:
predictor of response to chemotherapy and survival in dogs with 22 cases (1974-1984), J Am Vet Med Assoc 189:214–217, 1986.
lymphoma: 96 cases (1993-2006), J Am Vet Med Assoc 231:1836– 406. Kleiter M, Hirt R, Kirtz G, et al.: Hypercalcaemia associated with
1842, 2007. chronic lymphocytic leukaemia in a Giant Schnauzer, Aust Vet J
387. Jagielski D, Lechowski R, Hoffmann-Jagielska M, et al.: A retro- 79:335–338, 2001.
spective study of the incidence and prognostic factors of multicen- 407. Workman HC, Vernau W: Chronic lymphocytic leukemia in dogs
tric lymphoma in dogs (1998-2000), J Vet Med A Physiol Pathol and cats: the veterinary perspective, Vet Clin North Am Small Anim
Clin Med 49:419–424, 2002. Pract 33:1379–1399, viii, 2003.